Table 2.
Summary of GSEA analysis of the vitamin D regulated differentially expressed genes using the Gene sets:
| Enriched# | Duodenum Undifferentiated | Type | Signi * | Duodenum Differentiated | Type | Signif |
|---|---|---|---|---|---|---|
| Vit D | Xenobiotics/Phase I functionalization/Cytochrom P450 | Reactome | F | Xenobiotics/Phase I functionalization/Cytochrom P450 | C5, Reactome | F |
| Busslinger duodenal differentiating stem cells | C8 | F | Busslinger duodenal mature enterocytes | C8 | F | |
| ILK target genes | C8 | F | Glucuronidation | Reactome | F | |
| Oxidative phorphorylation/Mitochondrial large and small subunit | C5 | F | TGF beta Receptor signaling to activate SMADS/Smad heterodimers | Reactome | F | |
| Eukaryotic translation initiation/elongation | Reactome | F | Rho GTPases activate PKNS/Cycle | Reactome | F | |
| Ribosome biogenesis/Ribonuclear protein complex | C5 | F | Cell extracell matrix interactions | Reactome | F | |
| Regulation of mitochondrial gene expression | C5 | F | Ephrin signaling | Reactome | F | |
| Control | Gao Large intestine adult CH MKI67 high cells | C8 | F | Gao Large intestine adult CH MKI67 high cells | C8 | F |
| Gao Large intestine 24W C2 MKP67 pos progenitor | C8 | Gao Large intestine 24W C2 MKP67 pos progenitor | C8 | F | ||
| Gao Small intestine 24W C3 enterocyte progenitor subtype 1 | C8 | F |
| Enriched | Colon Undifferentiated | Type | Signif | Colon Differentiated | Type | Signif |
|---|---|---|---|---|---|---|
| Vit D | Bussinger Duodenal mature enterocytes | C8 | F | Abnormality of Vitamin D metabolism | C5 | F |
| GAO Large intestine 24W C1 DCLK1 Pos progenitor | C8 | F | Xenobiotics/Phase I functionalization/Cytochrom P450 | Reactome | F | |
| Glucuronidation | Reactome | F | ||||
| Rho GTPases activate PKNS | Reactome | F | ||||
| Base excision repair | Reactome | F | ||||
| Control | Wnt protein binding | C5 | F | GAO_Small intestine 24W C6 Goblet cells | C8 | F |
| O linked glycosylation | Reactome | F |
# Vit D = pathways enriched in the 1,25(OH)2D-treated group; Control = pathways enriched in the vehicle group; * F = 10% FDR.